ArticleHuman vaccines & immunotherapeutics2026
Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19.
Sophie Grice, Joshua Gardner, Paul Thomson, Luisa Hering, Lonnie MacDonald, Stacey Collins, Lance Turtle, Daniel F Carr, Anna Olsson-Brown, Sean Hammond and 1 more
Abstract read
In one paragraphArticle in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Sophie GriceCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0001-8355-4233 Joshua GardnerCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0002-4520-108X Paul ThomsonCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0001-5431-0459 Luisa HeringCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0002-5736-8725 Lonnie MacDonaldCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Stacey CollinsCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Daniel F CarrCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0001-8028-4282 Anna Olsson-BrownCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0001-7721-5817 Sean HammondCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Dean J NaisbittCentre for Drug Safety Science, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0003-4107-7832 Funding
Wellcome Trust
6 · The paper itselfAbstract
An extensive body of clinical and experimental evidence demonstrates that immune checkpoint blockade can invigorate recall immune responses. This phenomenon has previously been highlighted using
Indexed as
COVID-19Immune Checkpoint InhibitorsImmunologic MemoryMemory T CellsSARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesChAdOx1 nCoV-19CytokinesFemaleHumansLeukocytes, MononuclearMaleChAdOx1 nCoV-19CytokinesImmune Checkpoint InhibitorsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19cytokinesImmune checkpoint inhibitorimmunotherapyT-cellsvaccines
Identifiers
PMID42836482
PMCPMC13644633
What OpenQuestion holds
Textmetadata
Read underepoch 390